Cigna Offers New Weight-Loss Drug Pricing Plan to Boost Use

Cigna Group is introducing a novel drug pricing model for weight-loss medications like Eli Lilly's Zepbound and Novo Nordisk's Wegovy, aiming to broaden patient access by lowering costs for both individuals and health plans. Patients will pay less than the cash price but more than a typical copay, while health plans will spend less than under standard coverage, incentivizing more employers to include these drugs in their formularies.

Analysis

Cigna Group's drug benefit unit has introduced an innovative pricing model for high-cost weight-loss medications, specifically Eli Lilly & Co.'s Zepbound (LLY) and Novo Nordisk A/S's Wegovy (NVO), aimed at expanding patient access. Under this new option, patient out-of-pocket expenses will be lower than the cash price but typically higher than standard copayments, while health plans will incur reduced costs for these drugs compared to existing structures. This design is intended to incentivize more employers to provide coverage for these treatments, thereby increasing their availability. The market has registered this development with a generally positive sentiment (overall score 0.3; LLY: 0.4, NVO: 0.4, CI: 0.3) and a moderate market impact score of 0.4, indicating an optimistic outlook on the potential for increased drug utilization. Such an increase could bolster sales volumes for Eli Lilly and Novo Nordisk, and may enhance Cigna's (CI) competitive standing within the pharmacy benefit management landscape by addressing a key cost concern for employers.

Key Decisions for Investors

• Investors should evaluate the potential for increased prescription volumes of Zepbound and Wegovy, which could positively impact revenues for Eli Lilly and Novo Nordisk due to broader patient access facilitated by Cigna's new plan.
• Consider monitoring Cigna's client acquisition and retention rates following the rollout of this pricing model, as its success could enhance the attractiveness of its drug benefit services to health plans and employers.
• Assess the broader implications for the GLP-1 drug market, as innovative pricing strategies addressing affordability could become a more significant factor in market penetration and competitive dynamics.